Skip to main content
NEWLAND PHARMACEUTICAL CO., LTD logo

NEWLAND PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 301277 ISIN · CNE1000065K2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2024-10-21 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 301277

About NEWLAND PHARMACEUTICAL CO., LTD

https://www.newlandpharma.com

Newland Pharmaceutical Co., Ltd. is a specialized enterprise engaged in the research, development, manufacturing, and global distribution of active pharmaceutical ingredients (APIs) and high-quality chemical intermediates. The company focuses on a broad spectrum of therapeutic categories, including cardiovascular, anti-infective, and metabolic health solutions. Operating with a commitment to rigorous quality control, its production facilities are designed to meet international Good Manufacturing Practice (GMP) standards. Newland Pharmaceutical prioritizes technological innovation and chemical synthesis optimization to deliver reliable pharmaceutical components. Its core operations involve the large-scale production of complex molecules, supporting the supply chains of healthcare providers and pharmaceutical formulators worldwide through a focus on technical excellence and regulatory compliance.

Recent filings

Filing Released Lang Actions
监事会议事规则
Governance Information Classification · 95% confidence The document is titled as the "Supervisory Board Meeting Rules" of a company, detailing the responsibilities, meeting procedures, voting rules, and operational guidelines of the supervisory board. It is a governance-related document outlining internal rules and procedures rather than financial data, audit results, or management reports. There is no indication of financial statements, audit opinions, or report announcements. The content aligns with governance practices and internal board rules rather than any other filing category. Therefore, the most appropriate classification is Governance Information (CGR).
2024-10-21 Chinese
公司章程
Governance Information Classification · 95% confidence The document is a detailed company charter or articles of association for 新天地药业股份有限公司 (Newland Pharmaceutical Co., Ltd.). It includes sections on company organization, shareholder rights, board and management structure, share issuance and transfer, shareholder meetings, and other governance matters. It references laws and regulations, shareholder meeting procedures, and internal company rules. There is no indication that this is an annual report, financial statement, earnings release, or any other financial filing. Instead, it is a governance document outlining the company's internal rules and structure. Therefore, the most appropriate classification is Governance Information (CGR). The document length and detail support this classification with high confidence.
2024-10-21 Chinese
第六届监事会第三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of 新天地药业股份有限公司 regarding their third meeting of the sixth session. It includes approval of the 2024 third quarter report proposal, adjustments to fundraising projects, and amendments to supervisory meeting rules. The document references other filings where the full 2024 third quarter report and related announcements are published on an external website (巨潮资讯网). The document itself is short (1940 characters) and primarily serves as a meeting resolution announcement rather than containing substantive financial data or the full report. It also includes voting results and procedural compliance statements. This fits best with the category of Regulatory Filings (RNS), as it is a regulatory announcement of meeting resolutions and approvals, not the full quarterly report or financial statements themselves.
2024-10-21 Chinese
关于获得化学原料药上市申请批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company about receiving an approval notice from the National Medical Products Administration for a chemical raw material drug listing application. It includes details about the drug, approval number, validity, and impact on the company. The document is short (1015 characters) and serves as an official announcement of regulatory approval rather than a financial report or detailed filing. It does not contain financial data, management changes, or meeting materials. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about a significant company event that does not fit other specific categories.
2024-10-09 Chinese
关于获得化学原料药上市申请批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company regarding the receipt of approval notices for chemical raw drug listings from the National Medical Products Administration. It details the approval of two chemical raw drugs, their specifications, and the impact on the company. The document is relatively short (1543 characters) and serves as a formal announcement of regulatory approval rather than a detailed financial or operational report. It does not contain financial statements, management discussion, or detailed analysis. Therefore, it fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2024-09-25 Chinese
2024年第一次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as a resolution announcement for the "2024 First Extraordinary General Meeting of Shareholders" of the company 新天地药业股份有限公司. It details the meeting date, attendance, voting results on specific proposals, and includes a legal opinion confirming the legality of the meeting and voting process. There is no financial data or report content, but rather the official announcement of the voting results from a shareholders meeting. This matches the definition of "Declaration of Voting Results & Voting Rights Announcements (DVA)". The document length is short (2106 characters) and focuses on voting outcomes, not on financial or management reports.
2024-08-29 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.